Efficacy of catheter-based drug delivery in a hybrid in vitro model of cardiac microvascular obstruction with porcine microthrombi.

Publication Year: 2023

DOI:
10.1002/btm2.10631

PMCID:
PMC10905539

PMID:
38435814

Journal Information

Full Title: Bioeng Transl Med

Abbreviation: Bioeng Transl Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Engineering, Biomedical

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT SF and RSS own stock and/or stock options in CorFlow Therapeutics AG. SF is an employee of CorFlow Therapeutics AG. SF, RSS and DO have a pending patent application for a microfluidic coronary circulation model. CorFlow Therapeutics AG partially funded the work of YR. YR, TS, MW, and NC and were provided free material (e.g., Occlusion‐infusion catheter) from CorFlow Therapeutics AG."

Evidence found in paper:

"FUNDING INFORMATION This study was financed over the (grants 25390.2PFLS‐LS, 31010.1IP‐LS, and 104.947 IP‐LS) from the Innosuisse – Schweizerische Agentur für Innovationsförderung."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025